Overview

TNF-Alpha Inhibition for Treatment of Alzheimer's Disease

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
Phase:
Phase 1
Details
Lead Sponsor:
Tobinick, Edward Lewis, M.D.
Treatments:
Etanercept